SRG-514 for Breast Cancer

Not yet recruiting at 2 trial locations
KA
Overseen ByKayti Aviano
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: SURGE Therapeutics
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have triple-negative breast cancer confirmed by current guidelines.
I have cancer in both breasts or in multiple areas, with each area confirmed by diagnosis.
I am scheduled for breast-conserving surgery to cure my breast cancer soon.
See 2 more

Exclusion Criteria

I am having immediate breast reconstruction using tissue from another part of my body.
I expect to need a drain after my breast-conserving surgery.
My cancer is at stage IV.
See 3 more

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: SRG-514 + BCS (breast conserving surgery)Experimental Treatment1 Intervention
Group II: BCSActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

SURGE Therapeutics

Lead Sponsor

Trials
3
Recruited
120+